Project Grant R03HL185266
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $811,885 to the J. David Gladstone Institutes under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025. The award funds research to elucidate epigenomic mechanisms of cardiac fibrosis and heart failure pathogenesis, with a completion date of May 31, 2029. The research leverages novel genetic mouse models, advanced transcriptional and epigenomic...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Trustees of Columbia University in the City of New York $1,537,970 under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025, with a completion date of March 14, 2026. This Project Grant supports mechanistic research investigating posttranscriptional RNA modifications in lung development and regeneration, specifically examining how the METTL3/14...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $1,151,500 to Columbia University's Health Sciences Division on March 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This seven-year project, extending through February 28, 2033, will investigate novel mechanisms of macrophage biology in atherosclerosis and its intersection with metabolic dysfunction-associated steatohepatitis (MASH). The research program will deliver...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University's Health Sciences Division a $1.39 million Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) effective August 5, 2025, with completion targeted for March 31, 2026. The project, titled "Epitranscriptomic Regulation in Hematopoietic Stem Cell Niche Generation and Regeneration," funds research investigating the role of N6-methyladenosine (M6A) mRNA...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $124,688 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cardiovascular Diseases Research program (CFDA 93.837) for a project grant running from April 1, 2026 through March 31, 2028. This K99/R00 career development award funds research to decode the gene regulatory networks governing mammalian cardiac maturation, addressing a critical gap in...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Trustees of Columbia University in the City of New York, Health Sciences Division, a Project Grant totaling $1.137 million under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective April 1, 2026, through January 31, 2033, funds research on "Dynamics and Plasticity of the Hematopoietic Stem Cell Niche." The project delivers fundamental scientific research...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $166,644 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on July 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research investigating inflammatory responses in human hematopoietic stem cells (HSCs) with a focus on understanding how aging and clonal hematopoiesis—specifically TET2 mutations—alter...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $553,217 to the University of Colorado-Denver on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). This research project, titled "Hat-Dependent Control of Cardiac Fibrosis," will extend through May 31, 2029, and focuses on understanding and developing targeted therapeutic interventions to prevent pathological fibrotic remodeling in the heart. The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Trustees of Columbia University in the City of New York a Project Grant totaling $1,151,498 under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective March 1, 2026, with completion targeted for January 31, 2033, funds research to advance understanding of lung epithelial regeneration and development as a means to address end-stage lung diseases such as idiopathic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Children's Hospital of Philadelphia Research Institute a $594,583 Project Grant effective August 10, 2025, through May 31, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). This research project, titled "Origins of Neonatal Lung Myofibroblasts," focuses on advancing understanding of myofibroblast development and function during neonatal lung maturation. The research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University's Health Sciences Division a Project Grant totaling $246,750 under the Cardiovascular Diseases Research program (CFDA 93.837) for the period July 1, 2026, through March 31, 2028. This R03 award funds research to elucidate fibrotic signatures and mechanisms following myocardial infarction (MI), with particular focus on identifying why the neonatal heart can resolve cardiac fibrosis while the adult heart cannot. The research will leverage proximity proteomics techniques to characterize secreted proteins and develop transgenic mouse models with biotinylated secretomes in cardiac fibroblasts, ultimately aiming to discover anti-fibrotic therapeutic approaches applicable to adult cardiovascular disease. The research deliverables include the generation of a novel genetic mouse model employing biotin ligase (TurboID) targeting to the endoplasmic reticulum in cardiac fibroblasts for in vivo secretome labeling, and comparative proteomic profiling between neonatal and adult hearts following MI. These products will advance understanding of fibrosis resolution mechanisms and contribute to therapeutic development for cardiac fibrosis, a common feature of ischemic heart disease, diabetes mellitus, and aging for which no current treatments exist.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $246.8k | 6/30/26 |